Omeros Corporation (NASDAQ:OMER) surged 65% in Wednesday’s premarket trading after announcing a landmark asset purchase and licensing agreement with Novo Nordisk (NYSE:NVO) for its MASP-3 inhibitor, zaltenibart.
Under the terms of the deal, Novo Nordisk will acquire exclusive global rights to develop and commercialize zaltenibart for all indications. Omeros will receive $340 million in upfront and near-term milestone payments, with total consideration potentially reaching $2.1 billion when including development and commercial milestones, plus tiered royalties on future net sales.
Zaltenibart — previously known as OMS906 — is a clinical-stage antibody designed to block MASP-3, a key protein in the complement system’s alternative pathway. Early Phase 2 data showed encouraging results in treating paroxysmal nocturnal hemoglobinuria (PNH), a rare disease that causes the immune system to destroy red blood cells.
Martin Holst Lange, Novo Nordisk’s Chief Scientific Officer, said, “Zaltenibart has a novel mode of action that could offer several advantages over other treatments for complement-mediated diseases.”
Once the deal closes, expected in the fourth quarter of 2025, Novo Nordisk intends to launch a global Phase 3 program for zaltenibart in PNH and evaluate its potential in other rare blood and kidney disorders.
Omeros will keep certain rights to its preclinical MASP-3 programs, excluding zaltenibart, and plans to pursue small-molecule MASP-3 inhibitors for select indications. The company will also continue to prioritize regulatory approval and commercialization of its drug narsoplimab, alongside advancing its broader development pipeline.
The transaction remains subject to customary regulatory and closing conditions.
Omeros Corporation stock price
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Some portions of this content may have been generated or assisted by artificial intelligence (AI) tools and been reviewed for accuracy and quality by our editorial team.